What is the appropriate vancomycin dosage, including loading and maintenance doses, for a patient with a serious burn‑wound infection, and how should it be adjusted in the setting of impaired renal function (creatinine clearance <50 mL/min)?

Vancomycin Dosing for Serious Burn-Wound Infections

For burn patients with serious infections, administer vancomycin 15-20 mg/kg (based on actual body weight) every 8-12 hours, targeting trough concentrations of 15-20 mg/L, with mandatory therapeutic drug monitoring due to significantly increased clearance in this population. 1

Initial Dosing Strategy

For Normal Renal Function (CrCl ≥50 mL/min)

Loading and Maintenance Approach:

• Initial dose: 15-20 mg/kg IV based on actual body weight every 8-12 hours 1
• Target trough: 15-20 mg/L for serious infections including burn-wound infections 1
• Infusion rate: Administer over at least 60 minutes; extend to 1.5-2 hours when individual doses exceed 1 g 1
• Maximum concentration: 5 mg/mL (up to 10 mg/mL in fluid-restricted patients, though this increases infusion reaction risk) 2

Critical caveat for burn patients: Standard dosing (1 g every 12 hours) achieves target troughs in <10% of burn patients 3. Burn patients demonstrate:

• Significantly increased vancomycin clearance (mean 5.9-7.03 L/h vs. 3.4 L/h in non-burn patients) 4, 5
• Shortened elimination half-life 6
• Higher dosing frequency requirements 6

Optimized burn-specific regimens (based on time post-burn):

• 48 hours to 14 days post-burn: 1.5 g IV every 8 hours, 1.75 g IV every 8 hours, 1 g every 6 hours, 1.25 g every 6 hours, or 750 mg every 4 hours 3
• >14 days post-burn: 1-1.25 g every 8 hours or 500 mg every 4 hours 3

These aggressive regimens only achieve target troughs 20-25% of the time, underscoring the absolute necessity of therapeutic drug monitoring 3.

Dosing with Impaired Renal Function (CrCl <50 mL/min)

Algorithmic approach:

1. Calculate creatinine clearance using Cockcroft-Gault equation 2:

   • Men: [Weight (kg) × (140 - age)] / (72 × SCr mg/dL)
   • Women: 0.85 × above value

2. Apply FDA dosing table 2:

   • CrCl 50 mL/min: 770 mg/24h
   • CrCl 40 mL/min: 620 mg/24h
   • CrCl 30 mL/min: 465 mg/24h
   • CrCl 20 mL/min: 310 mg/24h
   • CrCl 10 mL/min: 155 mg/24h

3. Loading dose remains critical: Give at least 15 mg/kg initially, even with renal impairment, to achieve prompt therapeutic concentrations 2

4. Maintenance dosing options:

   • For marked renal impairment: 250-1000 mg every several days rather than daily 2
   • For anuria: 1000 mg every 7-10 days 2

Important consideration for burn patients with renal impairment: The relationship between vancomycin clearance and creatinine clearance remains linear in burn patients (CL_Van = 0.0205 × CrCl + 3.47) 5, 7. However, burn patients clear vancomycin similarly to non-burn patients at equivalent levels of renal function 7, so renal function-based adjustments apply but must account for the baseline increased clearance.

Therapeutic Drug Monitoring Protocol

Mandatory monitoring approach:

• First trough: Before the 4th dose at steady state 1
• Frequency: More frequent monitoring required in burn patients due to pharmacokinetic heterogeneity and temporal changes 3, 4
• Target range: 15-20 mg/L for serious infections 1
• Additional monitoring indications:
  • Unstable renal function (improving or deteriorating) 1
  • Concurrent nephrotoxic agents 1
  • Aggressive dose targeting 1

Do not monitor peak concentrations - this does not reduce nephrotoxicity risk 1

Critical Pitfalls in Burn Patients

1. Underestimating clearance: Burn patients have 1.7-fold higher clearance than controls 4. Standard nomograms were not developed for these targets and will fail 1.

2. Temporal pharmacokinetic changes: Vancomycin clearance differs significantly between 48h-14 days post-burn versus >14 days post-burn 3. Reassess dosing as time from injury increases.

3. Renal function estimation: In burn patients with low serum creatinine, Cockcroft-Gault-based estimates show better agreement with actual vancomycin clearance than other methods 8. The combined creatinine-cystatin C estimate may provide superior accuracy when available 9.

4. MIC considerations: If the organism's vancomycin MIC is ≥2 mg/L, achieving target AUC/MIC of ≥400 is not achievable with conventional dosing in patients with normal renal function - consider alternative therapies 1.

Nephrotoxicity Monitoring

Define vancomycin-induced nephrotoxicity as: ≥2-3 consecutive serum creatinine increases of ≥0.5 mg/dL or ≥50% from baseline after several days of therapy, absent alternative explanations 1. Monitor trough concentrations closely when targeting 15-20 mg/L, especially with concurrent nephrotoxins 1.